Abstract
As the COVID-19 pandemic rages globally, interest in antiviral treatments has never been higher. Antibodies are key defence components, and engineering them to better exploit their natural functions might boost therapeutic options. Modification of the antibody Fc domain boosts defence responses.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
